Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Mar;29(3):401-5.
doi: 10.1002/mds.25750. Epub 2013 Dec 27.

Results of the citalopram to enhance cognition in Huntington disease trial

Leigh J Beglinger  1 , William H Adams, Douglas Langbehn, Jess G Fiedorowicz, Ricardo Jorge, Kevin Biglan, John Caviness, Blair Olson, Robert G Robinson, Karl Kieburtz, Jane S Paulsen
Affiliations
Randomized Controlled Trial

Results of the citalopram to enhance cognition in Huntington disease trial

Leigh J Beglinger et al. Mov Disord. 2014 Mar.

Abstract

Background: The objective of this study was to evaluate citalopram for executive functioning in Huntington's disease (HD).

Methods: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and placebo run-ins. The primary outcome was change in executive functioning.

Results: The intent to treat analysis was controlled for practice effects, comparing visits 1 and 2 to visits 5 and 6 for citalopram versus placebo. There were no significant benefits on the executive function composite (treatment-placebo mean difference -0.167; 95% confidence interval [CI], -0.361 to 0.028; P = .092). Citalopram participants showed improved clinician-rated depression symptoms on the HAM-D (t = -2.02; P = 0.05). There were no group differences on motor ratings, self-reported executive functions, psychiatric symptoms, or functional status.

Conclusions: There was no evidence that short-term treatment with citalopram improved executive functions in HD. Despite excluding patients with active depression, participants on citalopram showed improved mood, raising the possibility of efficacy for subsyndromal depression in HD.

Trial registration: ClinicalTrials.gov NCT00271596.

Keywords: Huntington disease; clinical trial; cognitive disorders/dementia; neuropsychological assessment.

PubMed Disclaimer

References

    1. Campodonico JR, et al. When does Huntington's disease begin? J Int Neuropsychol Soc. 1998;4(5):467–73. - PubMed
    1. Lawrence AD, et al. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain. 1998;121( Pt 7):1329–41. - PubMed
    1. Paulsen JS, et al. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 2001;57(4):658–62. - PubMed
    1. Marder K, et al. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology. 2000;54(2):452–8. - PubMed
    1. Lange KW, et al. Comparison of executive and visuospatial memory function in Huntington's disease and dementia of Alzheimer type matched for degree of dementia. J Neurol Neurosurg Psychiatry. 1995;58(5):598–606. - PMC - PubMed

Publication types

Associated data